Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$39.50 USD
-1.59 (-3.87%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $39.49 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Xenon Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -182.39 | -125.37 | -78.88 | -28.84 | -41.60 |
Depreciation/Amortization & Depletion | 3.54 | 1.62 | 0.91 | 0.86 | 0.95 |
Net Change from Assets/Liabilities | 5.64 | -0.68 | -2.65 | -26.09 | 33.52 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 27.89 | 26.00 | 11.12 | 5.94 | 2.49 |
Net Cash From Operating Activities | -145.33 | -98.43 | -69.50 | -48.12 | -4.63 |
Property & Equipment | -5.62 | -2.89 | -2.05 | -2.64 | -1.24 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -111.55 | -293.11 | -244.72 | -14.19 | -65.05 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -117.17 | -296.00 | -246.77 | -16.82 | -66.29 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 353.52 | 278.47 | 447.54 | 102.54 | 27.52 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | -16.74 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 353.52 | 278.47 | 447.54 | 85.80 | 27.52 |
Effect of Exchange Rate Changes | 0.38 | -2.48 | -0.59 | -0.59 | 0.41 |
Net Change In Cash & Equivalents | 91.40 | -118.45 | 130.68 | 20.25 | -43.00 |
Cash at Beginning of Period | 57.24 | 175.69 | 45.01 | 24.76 | 67.75 |
Cash at End of Period | 148.64 | 57.24 | 175.69 | 45.01 | 24.76 |
Diluted Net EPS | -2.73 | -2.06 | -1.77 | -0.81 | -1.54 |
Fiscal Year End for Xenon Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -182.39 | -137.65 | -89.19 | -41.73 |
Depreciation/Amortization & Depletion | NA | 3.54 | 2.69 | 0.96 | 0.35 |
Net Change from Assets/Liabilities | NA | 5.64 | 6.16 | 9.46 | 2.56 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 27.89 | 18.94 | 11.15 | 4.40 |
Net Cash From Operating Activities | NA | -145.33 | -109.86 | -67.63 | -34.41 |
Property & Equipment | NA | -5.62 | -5.54 | -4.34 | -2.21 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -111.55 | 128.10 | 78.86 | 48.83 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -117.17 | 122.56 | 74.52 | 46.62 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 353.52 | 29.51 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 353.52 | 29.51 | 0.00 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.38 | 0.13 | 0.42 | 0.06 |
Net Change In Cash & Equivalents | NA | 91.40 | 42.33 | 7.31 | 12.27 |
Cash at Beginning of Period | NA | 57.24 | 57.24 | 57.24 | 57.24 |
Cash at End of Period | NA | 148.64 | 99.57 | 64.55 | 69.51 |
Diluted Net EPS | NA | -0.65 | -0.73 | -0.72 | -0.63 |